Suppr超能文献

血管扩张剂与β受体阻滞剂的相互作用——其临床成功的一些决定因素。

The vasodilator--beta-blocker interaction--some determinants of its clinical success.

作者信息

Zacest R

出版信息

Aust N Z J Med. 1976 Aug;6(3 Suppl):65-76. doi: 10.1111/j.1445-5994.1976.tb03339.x.

Abstract

A number of structurally dissimilar compounds, sharing the ability to induce vasodilatation have come into clinical usefulness as antihypertensive drugs. Their successful utilisation often depends critically on an appropriate combination with diuretics and beta-blockers. Beta-blockers can specifically inhibit the reflex cardiac stimulation which otherwise may limit the tolerability and haemodynamic value of these drugs. A synergistic antihypertensive effect has been demonstrated with hydrallazine and propranolol and possibly exists with other combinations. Generally, vasodilators are not first-line drugs in chronic therapy but are best added to beta-blockers. Variations of the dose-response and the time-course of effect are stressed as being important determinants of a successful interaction.

摘要

许多结构不同但具有诱导血管舒张能力的化合物已作为抗高血压药物投入临床使用。它们的成功应用往往严重依赖于与利尿剂和β受体阻滞剂的适当联合使用。β受体阻滞剂可特异性抑制反射性心脏刺激,否则可能会限制这些药物的耐受性和血流动力学价值。已证明肼屈嗪和普萘洛尔具有协同降压作用,其他联合用药可能也存在这种作用。一般来说,血管扩张剂在慢性治疗中不是一线药物,最好与β受体阻滞剂联合使用。剂量反应和效应时间过程的变化被强调为成功相互作用的重要决定因素。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验